Pharmacy Podcast Network

The Moderna COVID-19 Vaccine - What Pharmacists Need to Know | Locked On Pharmacy

On December 18, 2020, the Food and Drug Administration authorized the emergency use of the Moderna vaccine, exactly one week after granting the same to the vaccine developed by Pfizer and BioNTech. Two days later, the Advisory Committee on Immunization Practices (ACIP) has issued its recommendations for the next two phases of vaccine allocation.
Our guests are Michael D. Hogue, president of APhA, and a member of a working group of health care leaders that has been advising CDC on the rollout of the vaccine; and Stephan Foster. a member of ACIP, who has also served as a faculty member at the University of Tennessee’s School of Pharmacy and as a captain with the US Public Health Service.
Resources referenced in this podcast:
FDA: Provider Guidance for the Moderna Vaccine (pdf)
FDA: Patient information about the Moderna Vaccine (pdf)
ACIP: Recommendations for Allocation Phase 1b and 1c (pdf)
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Looking Back on 2020 | PUTTcast Episode 12

The PUTTcast Episode 12: Looking Back on 2020
Join hosts PUTT Executive Director Monique Whitney, and Board President Scott Newman; with PUTT board members Lauren Young, Jeremy Counts, & Van Coble as they take a look back over the events of 2020 and discuss what this could mean for pharmacies in the upcoming year. 
Join the Fight: 
https://www.truthrx.org/rxrevolution.html 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Keep Your Poop to Yourself | GameChangers

Clostridioides difficile is an important cause of morbidity and mortality in the United States with over 500,000 infections annually. The Infectious Disease Society of America released a clinical quality measure focused on treatment of c diff in March 2020. A review of the diagnosis and treatment will help providers improve quality.
This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!
The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

PCSK9 Inhibitors | Pharmacy Connect Podcast

Pharmacy Connect Podcast: PCSK9 Inhibitors Title: PCSK9 Inhibitors:Understanding the Pharmacist’s Role in Patient Education and Improving Outcomes With Hyperlipidemia Management Special guest: Joseph Saseen, PharmD Professor and Vice Chair, Clinical and Academic Programs; Department of Clinical Pharmacy      Skaggs School of Pharmacy and Pharmaceutical Sciences     University of Colorado Anschutz Medical Campus Objectives Understand the role of PCSK9 inhibitors in the American Heart Association and the American College of Cardiology hyperlipidemia management guidelines Review the pertinent drug information and clinical benefits of the use of PCSK9 inhibitors in the treatment of hyperlipidemia. Describe the role of the pharmacist in patient education and counseling on PCSK9 inhibitors for the treatment of hyperlipidemia through motivational interviewing. CE LINK HERE: https://www.pharmacytimes.org/on-demand/pcsk9-inhibitors-understanding-the-pharmacists-role-in-patient-education-and-improving-outcomes-with-hyperlipidemia-management PTCE - Pharmacy Times Continuing Education See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Supreme Court Rules in Favor of Pharmacy | Locked On Pharmacy

On Dec. 10, 2020, the U.S. Supreme Court ruled 8-0 that an Arkansas law regulating how PBMs and pharmacies interact could be enforced, and was not preempted by federal law.
With more than three dozen other states debating or passing such legislation, the ruling could have nationwide impact. The CEOs of national pharmacy organization were unanimous in hailing the decision.
In this episode, three guests discuss the case: Rep. Buddy Carter (R-Georgia); John Vinson, CEO of the Arkansas Pharmacists Association; and Scott Knoer, Executive Vice President and CEO of the American Pharmacists Association.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Enhancing Diabetes Management: Important Technological and Therapeutic Achievements

For over a century, the treatments and technologies used to treat diabetes have evolved. New tools are now available to aid in diabetes management and to help patients further manage and better control their glucose levels.
1,2 Through their recently announced collaboration, Dexcom and Lilly are at the forefront of enhancing diabetes care.
3 In this episode Dr. Chad Worz and guest speakers Deirdre Ibsen and Dr. Thomas Blevins discuss these important technological and therapeutic achievements over time, as well as 2 products available from Dexcom and Lilly and how they may benefit patients with diabetes.
References: 
Dexcom G6 Pro User Guide. https://dexcompdf.s3-us-west-2.amazonaws.com/Dexcom-G6-Pro-User-Guide.pdf. Accessed October 12, 2020.
Lyumjev [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
Eli Lilly and Company. Lilly and Dexcom team up on new program to help improve diabetes management. https://provider.dexcom.com/products/dexcom-g6-pro/training-resources. Accessed October 12, 2020.
Centers for Disease Control. National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed October 1, 2020.
American Diabetes Association. Diabetes and Quality of Life. http://journal.diabetes.org/diabetesspectrum/00v13n1/pg48.htm. Accessed October 1, 2020.
American Diabetes Association. Caring for the Caregiver. https://spectrum.diabetesjournals.org/content/17/1/37.full-text.pdf. Accessed October 15, 2020.
Ali MK, Bullard KM, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;369(3):287-288.
Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.
American Diabetes Association. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(suppl 1):S77-S88.
Hirsch IB. History of Glucose Monitoring. https://professional.diabetes.org/sites/professional.diabetes.org/files/media/db201811.pdf. Accessed October 1, 2020.
White JR. A brief history of the development of diabetes medications. Diabetes Spectr. 2014;27(2):82-86.
Science History Institute. Frederick Banting, Charles Best, James Collip, and John Macleod. https://www.sciencehistory.org/historical-profile/frederick-banting-charles-best-james-collip-and-john-macleod. Accessed October 1, 2020.
American Diabetes Association. Timeline. https://www.diabetes.org/resources/timeline. Accessed October 9, 2020.
Humalog [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
Selam J-L. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010;4(3):505-513.
American Association of Diabetes Educators. Insulin Injection Know-How. https://www.diabeteseducator.org/docs/default-source/legacy-docs/_resources/pdf/general/Insulin_Injection_How_To_AADE.pdf. Accessed October 1, 2020.
Hyllested-Winge J, Jensen KH, Rex J. A review of 25 years’ experience with the NovoPen® family of insulin pens in the management of diabetes mellitus. Clin Drug Investig. 2010;30(10):643-674.
Eli Lilly and Company. Lilly Launches KwikPen(TM) for Humalog(R) and Humalog Mixtures [press release]. https://investor.lilly.com/news-releases/news-release-details/lilly-launches-kwikpentm-humalogr-and-humalog-mixtures. Accessed October 12, 2020.
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(suppl 1):S66-S76.
Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107-139.
Fonseca VA, Grunberger G, Anhalt H, et al. Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract. 2016;22(8):1008-1021.
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603.
Dexcom G6 Pro Unblinded Patient Guide. https://dexcompdf.s3-us-west-2.amazonaws.com/Dexcom-G6-Pro-Unblinded-Patient-Guide.pdf. Accessed October 12, 2020.
Dexcom Announces FDA Clearance of New Dexcom G6 Pro CGM. https://provider.dexcom.com/industry-news/fda-authorizes-dexcom-g6-pro. Accessed October 2, 2020.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. 2017;317(4):371-378.
Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365-374.
Polonsky WH, Hessler D, Ruedy KJ, Beck RW. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care. 2017;40(6):736-741.
Pratley RE, Kanapka LG, Rickels MR, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. 2020;323(23):2397-2406.
Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11(6):1138-1146.
Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. 2017;317(4):379-387.
Frequently Asked Questions. https://provider.dexcom.com/products/dexcom-g6-pro/faqs. Accessed October 15, 2020.
Dexcom Products: Dexcom G6 Pro. https://provider.dexcom.com/products/professional-cgm. Accessed October 15, 2020.
How to Customize Alarm and Alerts. https://www.dexcom.com/faqs/how-to-customize-alarm-and-alerts. Accessed October 15, 2020.
Trend Arrows and Treatment Decisions. https://s3-us-west-2.amazonaws.com/dexcompdf/HCP_Website/LBL015804+G6+Trend+Arrows+and+Treatment+Decisions.pdf. Accessed October 15, 2020.
Why CGM? https://provider.dexcom.com/why-cgm. Accessed October 12, 2020.
Pharmacy Coverage. https://provider.dexcom.com/pharmacy-coverage. Accessed October 12, 2020.
Is There Reimbursement for Using Dexcom G6 Pro? https://provider.dexcom.com/faqs/there-reimbursement-using-dexcom-g6-pro. Accessed October 12, 2020.
Hypoglycemia Unawareness. https://provider.dexcom.com/education-research/clinical-evidence/clinical-studies/real-time-continuous-glucose-monitoring-cgm. Accessed October 15, 2020.
Garg SK, Wernicke-Panten K, Wardecki M, et al. Safety, immunogenicity, and glycemic control of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes also using insulin glargine: 12-month results from the GEMELLI 1 trial. Diabetes Technol Ther. 2020;22(7):516-526.
Dexcom G6 Pro Blinded Patient Guide. https://dexcompdf.s3-us-west-2.amazonaws.com/HCP_Website/Dexcom+G6+Pro+Resources/LBL017177+Rev+004+Artwork%2C+Dexcom+G6+Pro+Blinded+Patient+Guide+US_r5_WEB.pdf. Accessed November 24, 2020.
Dexcom CLARITY Diabetes Management Software. https://www.dexcom.com/clarity. Accessed May 15, 2020.
Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. Published online July 2, 2020. doi: 10.2337/dc19-2550.
Klaff L, Cao D, Dellva MA, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020;22(10):1799-1807.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

What are ’Learning Health Systems’ special guest Allen Flynn, PhD, PharmD | FutureDose.tech

Todays FutureDose.tech guest is Allen Flynn, PhD & PharmD,  Assistant Professor, Department of Learning Health Sciences at the University of Michigan. 
It has been reported that 70% of pharmacists’ time is spent on non-cognitive activities such as medication distribution. As such, the industry recognizes that more automation is needed so that pharmacists and pharmacy technicians can spend more time on patient focused activities that improve outcomes. Allen Flynn, PhD & PharmD, is one of the industry trailblazers researching and building tools that will enable pharmacists to spend more time by the bedside.
Listen in as David Berkowitz and Allen Flynn discuss some of the problems that need to be solved from a clinical and technical perspective in order to automate more non-value added pharmacy tasks.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

POP CULTURE: Black Panther’s Heart-Shaped Herb | Let’s Pharmonize

The Black Panther proves to be more medically accurate than you might think. In this episode, our hosts are joined by friend and classmate Justin Frederick to discuss the realism of the heart-shaped herb; the source of the Black Panther's powers. We discuss ayahuasca, why cat's always land on their feet, and whether or not Cal should watch "The Black Panther," (he should.) All that and more on Let's Pharmonize!
This is NOT your physician's podcast. Hosts Shane Garrettson and Cal Vandergrift dive into the pharmacy world with fun, interesting, and downright weird topics!
Tune in for NEW episodes, available on Spotify, Apple, Anchor, and more! Check out our Facebook, Twitter, and Instagram pages at Let's Pharmonize to view videos and images relevant to every episode! If you have any questions, comments, or even corrections, e-mail us at pharmonization@gmail.com.
PLEASE READ: Shane and Cal are NOT medical professionals. DO NOT USE the information presented in this podcast to aid in your own personal health or medicinal benefit. This is a light-hearted podcast that should not be taken with the same seriousness as your own personal health,
A special thanks to Kelly Kerr for creating the music used in the intro and outro.
Audio from Black Panther owned by Disney Studios.
All Rights Reserved
This episode is sponsored by: 
CEimpact: https://www.ceimpact.com/podcast 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Pfizer-BioNTech Vaccine: What Pharmacists Need to Know | Locked on Pharmacy

Following the emergency authorization of the Pfizer-BioNTech COVID-19 vaccine we spoke with two pharmacy experts in immunization to talk about what it means for pharmacists. Our guests:
Michael Hogue, president of the American Pharmacists Association, Dean of the Loma Linda University College of Pharmacy, and a member of a special work group of health care leaders advising CDC on the rollout of the COVID vaccine.
Stephan Foster, PharmD, FAPhA, CAPT (Ret.), U.S. Public Health Service, and APhA liaison to the Advisory Committee on Immunization Practices. 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Geoff Didn’t Know Which Was Worse | GameChangers

The question of acetaminophen versus ibuprofen may finally be laid to rest. A recent meta-analysis compared the efficacy and safety of ibuprofen versus acetaminophen for the treatment of fever or pain in children younger than 2 years. Is there a drug of choice?
Reference: Tan E, Braithwaite I, McKinlay CJD, Dalziel SR. Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(10):e2022398. doi:10.1001/jamanetworkopen.2020.22398
This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!
The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Advocates for Safe IV Preparation Practices Share Their Inspiration | Future of Pharmacy Podcast

The Future of Pharmacy Podcast, presented by Omnicell
Episode 2
Advocates for Safe IV Preparation Practices Share Their Inspiration
Learn how a tragic medication error helped to inspire the formation of THRIV—a safety coalition comprised of healthcare providers, consumers and technology developers. THRIV seeks to protect patients from being harmed, and to protect caregivers from unwittingly doing harm—harm which too often stems from mistakes made when IVs are manually prepared.
Our host:
Ken Perez, Vice President, Healthcare Policy, Omnicell
Guests: 
Mark Neuenschwander, Founding Director, THRIV
Derek Gillespie, BPharm, MBA, Pharmacy Operations Manager, Renown Health
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

How 2020 Changed Healthcare | The Corepreneur Podcast

What a year 2020 has been. One thing is certain: business will never be the same again. So get ready to turn the page because 2021 is just around the corner — and it’s bringing with it all sorts of new opportunities. No more of the negative and definitely no more of the old. It is time for us to collectively look ahead.
In today’s episode, we’ll discuss how journalists filter the news, what’s ahead for The Corepreneur Podcast in 2021, and what 2020 looked like for a variety of business endeavors across healthcare.
This episode of the Corepreneur Podcast is sponsored by CEimpact. Learn more about CEimpact's online Continuing Education platform designed for career driven & innovative pharmacists at http://www.CEimpact.com 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Myoshia Boykin-Anderson, From Nowhere to Tech Millionaire | The Corepreneur Podcast with Anne Arvizu

Myoshia Boykin-Anderson discusses how she started her first business, how spirituality and business intersect, and why her secret lake house is so important to her.
“I do not let 'no' be the final answer for me." - Myoshia Boykin-Anderson.
Learn more about this episode of The Corepreneur Podcast with Anne Arvizu at www.annearvizu.com/11 
This episode of the Pharmacy Podcast is sponsored by UltiGuard Safe Pack
UltiGuard Safe Pack is the only pen needle product that comes with an all-in-one sharps container. Learn more about why UltiGuard Safe Pack is the best choice for your patients and your pharmacy. Learn more UltiGuard Safe Pack https://www.ulticare.com/ultiguard-safe-pack/podcast  
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Optimal Skin Care | Classy Chemist Podcast

On this episode of the Classy Chemist Podcast with Sarina Mughal we talk about optimal skin care & a pharmacist's insights.  Listen, learn, and share this very exciting episode introducing a fellow pharmacist and owner of a skincare brand inspired by his ethnicity and love for travel. 
Sponsored by: Dilma Herbals
Founder: Gaurav Gupta
Website: https://dilmaherbals.co.uk/
Instagram: @dilmaherbals 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Trusting your Pharmacist, Patient’s Safety, & Prescription Packaging | RxSafe Podcast Series

These days, your patients may be wondering, "How many people touch these pills before I take them?!" COVID-19 has increased pressure on healthcare providers to consider the use of “touchless technology” and other best practices to reduce disease transmission and keep patients safe.
This podcast episode will discuss consumer demand for 'no contact' medication packaging, and how you can differentiate your pharmacy and increase customer loyalty by providing safe, accurate, and untouched prescriptions.
As compliance packaging becomes increasingly popular, pharmacy owners are starting to look at dispensing costs -- not in terms of drug wholesale costs, rebates and DIR fees -- but in terms of vials versus blisters, or vials versus pouches.
After all, reimbursement doesn't change based on the packaging. The patients are prescribed the same NDCs, and their copay is the same regardless of whether the drugs go into a little amber bottle, a 7-day blister pack, or a strip of pouches labeled, ‘morning,’ ‘afternoon,’ and ‘evening.’
But what about your pharmacy costs, and specifically your dispensing costs -- including labor and materials -- for getting the scripts into the patients’ hands?
Regular readers of our blog may remember we already conducted a deep dive into the cost of strip packaging consumables last year. Consumable costs for our RapidPakRx™ strip packaging system are demonstrably lower than competing systems. 
Special Guests: 
Joe Williams, Brisson Pharmacy
Roberta Vining, Riley's Drugs
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

I Shrunk the Pandemic! | GameChangers

In the never ending battle with COVID-19, new studies have demonstrated a role for IVIG in the treatment of acute COVID-19 pneumonia, the potential benefit of honey and black seed in mild to moderate COVID-19, and the efficacy of an mRNA vaccine. What does this all mean for current practice?
Additional References:
IVIG: Gharebaghi, N., Nejadrahim, R., Mousavi, S.J. et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis 20, 786 (2020). https://doi.org/10.1186/s12879-020-05507-4 
Honey: Ashraf S, Ashraf S, Imran M, et al. Efficacy of honey and Nigella sativa against COVID-19: HNS-COVID-PK Trial. medRxiv 2020.10.30.20217364; doi: https://doi.org/10.1101/2020.10.30.20217364 
Cleveland Clinic Hospitalization Risk for COVID-19 Positive Calculator: https://riskcalc.org/COVID19Hospitalization/ 
Cleveland Clinic Predict COVID-19 test result Calculator: https://riskcalc.org/COVID19/ 
This episode is accredited for CPE. Subscribe at CEimpact https://www.ceimpact.com/pharmacist and claim your CE today!
The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Changing of the Guard | Beyond the Sig

The Pennsylvania Pharmacists Association (PPA) Board of Directors has named Victoria E. Elliott, RPh, MBA, CAE as Chief Executive Officer.  Elliott will succeed Patricia A. Epple, CAE, who is retiring at the end of 2020.
“Pat has been an outstanding leader of PPA for the last almost two decades,” said Chuck Kray, president of PPA. “She is leaving a strong organization in the hands of an equally strong successor. We are looking forward to welcoming Victoria Elliott.” Epple has been with PPA since 2002.
As CEO, Elliott will blend her training as a registered pharmacist with her 24 years of experience in association management to lead PPA in its mission promoting the profession through advocacy, education, and communication to enhance patient care and public health. She will manage PPA operations, membership growth and engagement, and all program development and implementation. In addition, she will oversee PPA’s affiliated entities including its Educational Foundation, the Pennsylvania Pharmacists Care Network, and PharmPAC – PPA’s political action committee. 
A Certified Association Executive since 2003, Elliott’s qualifications include alliance-building, volunteer engagement, board governance, leading legislative advocacy, and grassroots efforts to affect laws and regulations that critically impact healthcare professionals and the patients they serve. “I look forward to joining the PPA management team and am excited to work with my pharmacy colleagues and the PPA Board of Directors to advance the state of pharmacy practice across Pennsylvania,” said Elliott.
Prior to this appointment, Elliott was the CEO of the Association for the Advancement of Wound Care (AAWC), where she led a management transition, implementation of a three-year strategic plan, a branding campaign, and the launch of a series of educational summits focused on critical wound care issues. She also served as Executive Director for the American Neurological Association, Dermatology Nurses’ Association, Attention Deficit Disorder Association, and the Society For Biomaterials at Association Headquarters, and was the Executive Director for the Pennsylvania Society of Health-System Pharmacists from 1998 to 2005.
Before her career in association management, Elliott spent six years as a pediatric pharmacist in the Jefferson Health System, and two years as the Assistant Director of Pharmacy at Hahnemann University Hospital. In addition to her pharmacy degree from the Philadelphia College of Pharmacy, now part of the University of the Sciences, Elliott earned an MBA in Health and Medical Services from Widener University.
She is a Past President of the Mid-Atlantic Society of Association Executives (MASAE) and the Delaware Valley Society of Association Executives. She is also a member of the American Society of Association, the organization that confers the CAE designation. Elliott is a recipient of the MASAE Service Award for her distinguished service to the Association and in 2001, was recognized by the Philadelphia College of Pharmacy as the Young Alumnus Award winner. 
Ms. Elliott will begin her new role on December 1, 2020.  PSHP congratulates Ms. Elliott on this appointment and looks forward to working with her, and PPA, on Pennsylvania pharmacy issues. 
Pennsylvania Society of Health System Pharmacists 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Importance of Medication Decision Support | First Data Bank

Everyone talks about clinical decision support—but what about ‘medication decision support’?
Clinical decision support (CDS) gets a lot of attention, but what about “medication decision support?” Increasingly, health system leaders are putting this issue front and center, especially as it relates to medication alerts that are integrated into EHR and clinician workflows. It’s important that medication alerts improve safety and quality while also making clinicians’ jobs easier. If not properly executed, these alerts can become a burden rather than a decision support tool.
In an interview, Anna Dover, PharmD, and Bob Katter can speak to best practices around medical decision support, including medication alerts:  
Fit the medication decision support into the user’s workflow without interrupting them—and make the alerts actionable.
Move alerts to the time when they are relevant and to the best person capable of understanding and making a decision about the risk/medication.
Use decision support that incorporates patient characteristics. We are going to see that alerts and decision support that rely only on medication lists and nothing more specific from the patient will start to fade away. That traditional approach, although very sensitive, is not very specific. In other words, the alert was good at telling you about a potential risk, but not good about telling you whether this specific patient was at higher or lower risk.
We know have the technical capability to leverage lab results, patient age, gender, diagnosis, and other factors to fire an alert when the risk is high—or automatically suppress an alert when the risk is low.
Leverage analytics for better medication decision support. By looking at the data being generated through prescribing, we can make predictions about how a clinician or set of clinicians will respond to alert-tuning or modification.
It’s possible to simulate and make educated guesses about whether an alert will have the intended effect and improve care, or whether it will cause additional burden to the prescriber.
Medication decision support can also go a step further: This data can be leveraged to make specific predictions about a patient, such as quantifying their risk of opioid addiction—or even better, their risk of facing a whole host of adverse drug events.
That determination may be based upon their genetics, co-morbidities, and current physical state.
The future of medication decision support will focus on a combination of curated, evidence-based rules/knowledge and AI-driven pattern recognition.
When we have better alerts, we can use analytics to prove that they work better; they can be installed side-by-side with traditional alerts to validate that an advanced system is safe and effective—ultimately enabling the removal of traditional alerts.
Monitor the impact of deployments, get feedback, and respond, in order to optimize.  It’s important to closely manage and maintain your knowledge system to reflect evidence and pivot as needed.
First Databank (FDB) is the largest drug database in the United States. Bob and Anna are in discussions with health systems, hospitals, and community and retail pharmacists on a daily basis and have in depth knowledge on pain points and opportunities related to the pharmacy industry across the healthcare landscape. Anna from a Pharm D’s perspective and Bob from a business leadership perspective.
Guests:
Anna Dover, PharmD, Director, Product Management, (FDB) 
LinkedIn profile: https://www.linkedin.com/in/anna-dover-02137117/
Bob Katter, President of First Databank (FDB) 
Bio on FDB website: https://www.fdbhealth.com/company/leadership/bob-katter
LinkedIn profile: https://www.linkedin.com/in/bobkatter/
This episode was sponsored by First Databank 
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Community Pharmacy Practice: Looking Back and Looking Forward | Beyond the Sig

In this episode of Beyond the Sig, Brooke Kulusich, a third-year student pharmacist at the University of Pittsburgh School of Pharmacy, sits down with Melissa S. McGivney, PharmD, FCCP, FAPhA who serves as Associate Dean for Community Partnerships and Professor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. As a national leader in advancing  pharmacist-provided patient care in the community for 20 years, Dr. McGivney shares her perspective on the progress our profession has made and the challenges that lie ahead.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Medication Adherence During The COVID-19 Pandemic | PsychU Community Podcast

Medication adherence has proven challenging for many individuals during the coronavirus pandemic. For all the convenience offered by virtual visits, they make it more difficult to administer injections or assess how patients are responding to medication. Difficulty obtaining refills or necessary lab work can be barriers to medication adherence, as well. Care coordination is especially important now, says Dr. Ehret, who also suggests that providers consider giving patients extra refills when warranted—and check in on patients most at risk for medication nonadherence.
Featuring:
Megan Ehret, PharmD, MS, BCPP
Associate Professor at the University of Maryland School of Pharmacy and PsychU Pharmacist Corner Advisor
Joseph Cirrincione, PharmD, MBA
Medical Science Liaison, Otsuka Pharmaceutical Development & Commercialization, Inc.
Megan Ehret, PharmD, MS, BCPP, is Associate Professor in the Department of Pharmacy Practice & Science at the University of Maryland School of Pharmacy. A board-certified psychiatric pharmacist, she is also PsychU’s Pharmacist Corner Section Advisor.
Joseph Cirrincione, PharmD, MBA, is Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc.
Speakers are paid consultants or employees of Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community.
The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis.
Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional.
No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices